March 2017

iMed.ULisboa researchers participate in IMI winning consortium

The Innovative Medicines Initiative (IMI) has recently recommended for funding LITMUS – Liver Investigation: Testing Marker Utility in Steatohepatitis, under IMI2 Call 9, Topic 5 on  Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD).

Quentin M. Anstee, Professor of Experimental Hepatology & Consultant Hepatologist at the Institute of Cellular Medicine, Newcastle University, UK coordinates the winning consortium of 47 academic and industrial leaders. Cecilia Rodrigues will be leading the group at iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa involved in this consortium.